The patents related to Spiriva Respimat are set to expire by 16th April 2031. Post this date, the possibility for generic versions of the drug to be rolled out is likely, thus providing more affordable access to patients.
Spiriva Respimat, which contains tiotropium bromide, is most often used to manage Chronic Obstructive Pulmonary Disease (COPD) symptoms. The active ingredient contributes to its efficacy by relaxing the muscles in the airways to improve breathing.
Spiriva Respimat holds a total of 13 patents, with one already having expired. The last remaining patent is expected to expire on 16th April 2031. Hence, Spiriva Respimat generic could potentially be released following this date. Below are the details of the patents: